期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 80, 期 1, 页码 31-35出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2020-217344
关键词
-
类别
资金
- European League Against Rheumatism
The Task Force aimed to create recommendations for the underserved patient group with difficult-to-treat rheumatoid arthritis by drafting a definition based on international survey data among rheumatologists, nurses, health professionals, and patients. The definition includes specific criteria for treatment failure and symptom characteristics that are considered problematic by both the healthcare provider and the patient. This proposed EULAR definition can be applied in clinical practice, trials, and serve as a foundation for future research.
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. Objective The Task Force in charge of the Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. Methods The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). Results The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of >= 2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. Conclusions The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据